Protection of macaques with diverse MHC genotypes against a heterologous SIV by vaccination with a deglycosylated live-attenuated SIV.

PloS One
Chie SugimotoKazuyasu Mori

Abstract

HIV vaccine development has been hampered by issues such as undefined correlates of protection and extensive diversity of HIV. We addressed these issues using a previously established SIV-macaque model in which SIV mutants with deletions of multiple gp120 N-glycans function as potent live attenuated vaccines to induce near-sterile immunity against the parental pathogenic SIVmac239. In this study, we investigated the protective efficacy of these mutants against a highly pathogenic heterologous SIVsmE543-3 delivered intravenously to rhesus macaques with diverse MHC genotypes. All 11 vaccinated macaques contained the acute-phase infection with blood viral loads below the level of detection between 4 and 10 weeks postchallenge (pc), following a transient but marginal peak of viral replication at 2 weeks in only half of the challenged animals. In the chronic phase, seven vaccinees contained viral replication for over 80 weeks pc, while four did not. Neutralizing antibodies against challenge virus were not detected. Although overall levels of SIV specific T cell responses did not correlate with containment of acute and chronic viral replication, a critical role of cellular responses in the containment of viral replication was suggest...Continue Reading

References

Nov 1, 1990·AIDS Research and Human Retroviruses·D A Regier, R C Desrosiers
Jun 12, 1998·Nature Medicine·J N ReitterR C Desrosiers
Mar 1, 2000·Proceedings of the National Academy of Sciences of the United States of America·S A MiguelesM Connors
Jun 29, 2002·Science·Brian GaschenBette Korber
Mar 21, 2003·Nature·Xiping WeiGeorge M Shaw
Jun 24, 2004·The Journal of Experimental Medicine·Tetsuro MatanoYoshiyuki Nagai
May 10, 2007·Molecular Biology and Evolution·Koichiro TamuraSudhir Kumar
Jul 12, 2008·Nature Reviews. Immunology·Philip J R Goulder, David I Watkins
Oct 8, 2008·The Journal of Experimental Medicine·Matthew R ReynoldsDavid I Watkins

❮ Previous
Next ❯

Citations

Sep 11, 2012·Nature Medicine·Yoshinori FukazawaLouis J Picker
May 8, 2013·Retrovirology·Junko S TakeuchiBéatrice Labrosse
Apr 11, 2013·Human Vaccines & Immunotherapeutics·Matthew S ParsonsNicole F Bernard
Aug 5, 2020·The Journal of Immunology : Official Journal of the American Association of Immunologists·Satoru WatanabeKazuyasu Mori

❮ Previous
Next ❯

Methods Mentioned

BETA
glycosylation
PCR
transfection

Software Mentioned

Graph pad Prism
MEGA4
Clustal W
ATGC

Related Concepts

Related Feeds

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.